Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China

被引：0
|
作者：
Yang, Lihua
Ma, Xiaoli
Liu, Yu-Chen
Zhao, Wen
Yu, Lihua
Qin, Maoquan
Zhu, Guanghua
Wang, Kai
Shi, Xiaodong
Zhang, Zhaoxia
Wang, Jingfu
Sun, Yuan
Dong, Lujia
Tsao, Shih-Ting
Zhang, Rui
Chang, Lung-Ji
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3335
引用
收藏
页数：2
相关论文
共 42 条
  • [41] Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)
    Sauter, Craig S.
    Riviere, Isabelle
    Bernal, Yvette J.
    Wang, Xiuyan
    Purdon, Terence J.
    Yoo, Sarah
    Moskowitz, Craig H.
    Giralt, Sergio
    Matasar, Matthew J.
    Curran, Kevin J.
    Park, Jae H.
    Sadelain, Michel
    Brentjens, Renier J.
    BLOOD, 2014, 124 (21)
  • [42] Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL).
    Sauter, Craig Steven
    Riviere, Isabelle
    Bernal, Yvette
    Wang, Xiuyan
    Purdon, Terence
    Yoo, Sarah
    Moskowitz, Craig H.
    Giralt, Sergio
    Matasar, Matthew J.
    Curran, Kevin Joseph
    Park, Jae Hong
    Sadelain, Michel
    Brentjens, Renier J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345